Company grows management team in preparation for the launch of its AI-driven algorithm for the diagnosis of Parkinson’s Disease.
GAINESVILLE, FL – neuropacsTM,
a leading innovator in AI-driven neurological diagnostics, today announced that Mr. Dwight L. Hulse MBA, MPA, CPA/CITP, CGMA, CA(BZ) will serve as their fractional Chief Financial Officer, effective immediately.
Mr. Hulse is the Founder, CEO, and The Profit CFO™ of D.L. Hulse Consulting, LLC, a CFO Advisory Services company that advises entrepreneurs, small and medium-sized business owners and nonprofit professionals on how to plan, run, and grow their businesses. He has over 30 years of professional international experience from performing audits and business consulting engagements for all-size companies in the U.S., Belize, and Central America. He obtained senior management experience through serving as a Resident Vice President for Citibank, N.A., and Manager of Business Consulting for Andersen. Additionally, his professional career includes past employment with Santa Fe College, the University of Florida, Deloitte, and Pannell Kerr Forster. Since 2012, he has actively served as an Incubator Resource and Professional Consultant to resident and associate members’ companies participating in the Santa Fe College Center for Innovation and Economic Development business incubator program advising them in the areas of planning, finance, and accounting.
Dr. Martin Handfield, the President and CEO of neuropacs commented: ”Mr. Hulse is the right partner for neuropacs at this juncture. He brings experience and expertise to the management team in business finance, regulatory compliance, and strategic planning. Mr. Hulse added: “I believe that all entrepreneurs should have access to world-class financial expertise, and I look forward to the opportunity to help neuropacs remove barriers to success and work collaboratively with their management to find better solutions together.”
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.